- Home
- ZBH vs EXEL Comparison
ZBH vs EXEL Comparison
Compare ZBH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBH | EXEL |
|---|---|---|
| Founded | 1927 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 14.0B |
| IPO Year | 2001 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ZBH | EXEL |
|---|---|---|
| Price | $92.24 | $56.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 21 |
| Target Price | ★ $101.00 | $46.50 |
| AVG Volume (30 Days) | 2.1M | ★ 2.2M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | ★ 1.22 | 0.79 |
| Revenue | ★ $8,231,500,000.00 | $452,477,000.00 |
| Revenue This Year | $4.96 | $13.61 |
| Revenue Next Year | $3.76 | $13.13 |
| P/E Ratio | $74.88 | ★ $70.09 |
| Revenue Growth | ★ 7.20 | N/A |
| 52 Week Low | $79.12 | $33.76 |
| 52 Week High | $108.29 | $57.57 |
Technical Indicators
Market Signals| Indicator | ZBH | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 58.09 |
| Support Level | $85.21 | $54.39 |
| Resistance Level | $96.45 | $57.57 |
| Average True Range (ATR) | 2.58 | 1.33 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 69.62 | 59.63 |
Price Performance
Historical ComparisonAbout ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.